OncoNano Medicine: Brett Giroir Appointed CEO To Advance Oncology Pipeline

OncoNano Medicine has appointed Brett P. Giroir as CEO. Giroir had been serving as chairman and interim chief executive and will continue leading the clinical-stage oncology company as it advances its therapeutic programs and partnerships.

OncoNano develops targeted cancer therapies through proprietary polymer technologies. Its platforms are designed to exploit characteristics of the tumor microenvironment to deliver therapeutic payloads more selectively.

The company’s clinical-stage program includes ONM-501, an immunotherapy candidate intended to stimulate an antitumor immune response. OncoNano is also evaluating applications of its platform across other payloads and cancer types.

As CEO, Giroir will oversee clinical development, preclinical research, business development, financing strategy, and potential collaborations with pharmaceutical and biotechnology companies.

His background includes senior roles spanning government, medicine, academic research, and healthcare policy. That experience may be particularly relevant as OncoNano moves programs through regulatory development and evaluates partnerships.

Giroir previously served as U.S. Assistant Secretary for Health. He also held the rank of admiral in the U.S. Public Health Service Commissioned Corps and has worked with government agencies, academic institutions, and private-sector healthcare organizations.

The board cited his scientific credibility, regulatory knowledge, and relationships across government and industry as important qualifications for the permanent CEO role.

OncoNano’s technology is designed to accommodate different therapeutic payloads, potentially creating partnership opportunities beyond candidates developed internally. A versatile delivery platform can allow a biotechnology company to work with external drug developers seeking greater selectivity or improved activity within tumors.

Giroir said the company has made progress in advancing its clinical-stage immunotherapy and developing a broader portfolio of targeted treatments. His priorities include moving those programs forward, adding partnerships, and bringing potential therapies closer to patients.

The appointment removes the interim designation from the leadership structure and gives OncoNano continuity as it enters its next development phase. Giroir’s previous work as chairman also gives him familiarity with the company’s scientific strategy, management team, investors, and board.

KEY QUOTES

“Having worked closely with the OncoNano team, I’ve seen firsthand the potential of our technology and the strength of our team. We have made significant progress, advancing a clinical-stage immunotherapy program and building a pipeline of targeted cancer therapies, while demonstrating the versatility of our technology across a broad range of therapeutic payloads. My focus will be on advancing these programs, expanding our partnerships and moving promising new therapies closer to patients.”

Brett P. Giroir, CEO of OncoNano Medicine

“Brett has been an exceptional steward of OncoNano as Chairman and Interim CEO, and the Board is confident he is the right leader for this next phase. His scientific credibility, regulatory experience and deep relationships across government and industry position the company to advance ONM-501, grow our partnerships and bring new options to patients with hard-to-treat cancers.”

John Dyett, OncoNano Medicine Director and Co-Founder and Managing Director of Salem Partners